Form 4: Inotiv EVP Granted 10,000 Stock Options

Inotiv, Inc.'s EVP, General Counsel & Secretary, Andrea Castetter, was granted 10,000 non-qualified stock options with a three-year vesting schedule.

Summary

• Andrea Castetter, EVP, General Counsel & Secretary of Inotiv, Inc. (NOTV), was granted 10,000 non-qualified employee stock options.
• The options have an exercise price of $0.5956 per share.
• The grant date for these options was January 15, 2026.
• The options will expire on January 15, 2036.
• The vesting schedule is 40% on the first anniversary of the grant date, 30% on the second anniversary, and 30% on the third anniversary, contingent on continued employment.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant). While not directly impacting immediate financial performance, it reflects standard corporate governance and incentive practices, which is mildly positive for executive retention and alignment.

Positives

• The grant of stock options serves as an incentive for the EVP to remain with the company and contribute to its long-term success.
• Aligns management's interests with those of shareholders through equity ownership.

Negatives

• Potential for future dilution if the options are exercised, though this is a standard aspect of equity compensation.

Risks

• The value of the options is dependent on the future stock price of Inotiv, Inc., which is subject to market fluctuations and company performance.
• The vesting schedule is subject to continued employment, meaning the options could be forfeited if employment ceases before full vesting.

Future Outlook

The options are subject to a three-year vesting period, with 40% vesting on the first anniversary of the grant date, 30% on the second, and 30% on the third, contingent on continued employment. This structure aims to incentivize long-term commitment and performance from the executive.

Industry Context

The granting of stock options to key executives is a common practice across various industries, including the life sciences and contract research organization (CRO) sector where Inotiv operates. It is a standard component of executive compensation packages designed to attract, retain, and motivate talent by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• The use of non-qualified stock options with a multi-year vesting schedule is a standard compensation practice for executive retention and performance incentives, comparable to practices at companies like Charles River Laboratories (CRL), LabCorp (LH), or Eurofins Scientific (ERF.PA) in the CRO space, which frequently utilize equity awards to compensate and incentivize their leadership teams.
• The specific vesting schedule (40%/30%/30% over three years) is a common structure, though variations exist across companies and executive levels.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from incentivized executive performance.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• The options will begin vesting on January 15, 2027, subject to Andrea Castetter's continued employment.
• Subsequent vesting events will occur on January 15, 2028, and January 15, 2029.

Key Dates

Keywords

Inotiv, NOTV, stock options, Form 4, insider transaction, equity compensation, Andrea Castetter, EVP, General Counsel, vesting